Biodesix announces pricing of $35.1 million upsized public offering of common stock

Boulder, colo.--( business wire )--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions. the gross proceeds to biodesix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by biodesix, are expected to be $35.1 million. the offering is expected to close on november 21, 2022, subject to customary closing conditions. additionally, biodesix has granted the underwriters a 30-day option to purchase up to an additional 4,575,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. all of the shares of common stock in the offering will be sold by biodesix.
BDSX Ratings Summary
BDSX Quant Ranking